Buoyed by new results from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's disease candidate from its Brainshuttle programme, a technology designed to ...

Shares in Ironwood Pharma fell by a third after it revealed that the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy before it can consider approval. The outcome of its ...

Change orientation to land scape to view the price table ...